JP2024510778A - １，３－置換シクロブチル誘導体及びその使用 - Google Patents
１，３－置換シクロブチル誘導体及びその使用 Download PDFInfo
- Publication number
- JP2024510778A JP2024510778A JP2023558324A JP2023558324A JP2024510778A JP 2024510778 A JP2024510778 A JP 2024510778A JP 2023558324 A JP2023558324 A JP 2023558324A JP 2023558324 A JP2023558324 A JP 2023558324A JP 2024510778 A JP2024510778 A JP 2024510778A
- Authority
- JP
- Japan
- Prior art keywords
- corneal
- pharmaceutically acceptable
- independently selected
- alkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166289P | 2021-03-26 | 2021-03-26 | |
| US63/166,289 | 2021-03-26 | ||
| PCT/IB2022/052720 WO2022201097A1 (en) | 2021-03-26 | 2022-03-24 | 1,3-substituted cyclobutyl derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024510778A true JP2024510778A (ja) | 2024-03-11 |
| JPWO2022201097A5 JPWO2022201097A5 (https=) | 2025-04-01 |
| JP2024510778A5 JP2024510778A5 (https=) | 2025-04-01 |
Family
ID=80999265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023558324A Pending JP2024510778A (ja) | 2021-03-26 | 2022-03-24 | １，３－置換シクロブチル誘導体及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11845730B2 (https=) |
| EP (1) | EP4313951A1 (https=) |
| JP (1) | JP2024510778A (https=) |
| KR (1) | KR20230162660A (https=) |
| CN (1) | CN117062804A (https=) |
| AR (1) | AR125196A1 (https=) |
| AU (1) | AU2022244467A1 (https=) |
| CA (1) | CA3214066A1 (https=) |
| IL (1) | IL307189A (https=) |
| MX (1) | MX2023011377A (https=) |
| PY (1) | PY2221203A (https=) |
| TW (1) | TW202304864A (https=) |
| UY (1) | UY39681A (https=) |
| WO (1) | WO2022201097A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR125196A1 (es) * | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
| WO2024062389A1 (en) * | 2022-09-21 | 2024-03-28 | Bausch + Lomb Ireland Limited | Crystalline polymorph forms of a trpv1 antagonist and formulations thereof |
| US20240148709A1 (en) * | 2022-11-08 | 2024-05-09 | Aisa Pharma, Inc. | Methods of treating eye pain and eye disorders |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006519806A (ja) * | 2003-03-07 | 2006-08-31 | グラクソ グループ リミテッド | 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。 |
| JP2007501246A (ja) * | 2003-02-11 | 2007-01-25 | アボット・ラボラトリーズ | バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害する縮合アザ二環式化合物 |
| WO2008007780A1 (fr) * | 2006-07-13 | 2008-01-17 | Kyowa Hakko Kirin Co., Ltd. | Dérivé du pentadiènamide |
| WO2012072512A1 (en) * | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists |
| JP2014510768A (ja) * | 2011-04-11 | 2014-05-01 | グラクソ グループ リミテッド | Ｔｒｐｖ１アンタゴニストとしてのｎ−シクロブチルイミダゾピリジンメチルアミン |
| JP2014514286A (ja) * | 2011-03-25 | 2014-06-19 | アッヴィ・インコーポレイテッド | Ｔｒｐｖ１拮抗薬 |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| RU2451014C2 (ru) | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| NZ577980A (en) | 2006-12-27 | 2012-01-12 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone derivatives |
| DE102010052781A1 (de) | 2010-11-30 | 2012-05-31 | Trw Automotive Gmbh | Befestigungsvorrichtung und Befestigungsbaugruppe zur Befestigung eines Gasgenerators und Fahrzeuginsassenrückhaltesystem |
| US9747862B2 (en) | 2015-11-02 | 2017-08-29 | Castar, Inc. | Method of immersive rendering for wide field of view |
| US10269906B2 (en) * | 2016-11-30 | 2019-04-23 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor device having two spacers |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| AU2019392904B9 (en) | 2018-12-07 | 2022-12-22 | University Of Maryland, Baltimore | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors |
| AR125196A1 (es) * | 2021-03-26 | 2023-06-21 | Novartis Ag | Derivados de ciclobutilo 1,3-sustituidos y sus usos |
-
2022
- 2022-03-22 AR ARP220100676A patent/AR125196A1/es unknown
- 2022-03-22 UY UY0001039681A patent/UY39681A/es unknown
- 2022-03-23 PY PY202202221203A patent/PY2221203A/es unknown
- 2022-03-24 JP JP2023558324A patent/JP2024510778A/ja active Pending
- 2022-03-24 EP EP22714016.7A patent/EP4313951A1/en active Pending
- 2022-03-24 CA CA3214066A patent/CA3214066A1/en active Pending
- 2022-03-24 AU AU2022244467A patent/AU2022244467A1/en active Pending
- 2022-03-24 US US17/656,313 patent/US11845730B2/en active Active
- 2022-03-24 WO PCT/IB2022/052720 patent/WO2022201097A1/en not_active Ceased
- 2022-03-24 CN CN202280024266.2A patent/CN117062804A/zh active Pending
- 2022-03-24 TW TW111111060A patent/TW202304864A/zh unknown
- 2022-03-24 KR KR1020237036535A patent/KR20230162660A/ko active Pending
- 2022-03-24 IL IL307189A patent/IL307189A/en unknown
- 2022-03-24 MX MX2023011377A patent/MX2023011377A/es unknown
-
2023
- 2023-10-24 US US18/493,441 patent/US12435040B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007501246A (ja) * | 2003-02-11 | 2007-01-25 | アボット・ラボラトリーズ | バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害する縮合アザ二環式化合物 |
| JP2006519806A (ja) * | 2003-03-07 | 2006-08-31 | グラクソ グループ リミテッド | 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。 |
| WO2008007780A1 (fr) * | 2006-07-13 | 2008-01-17 | Kyowa Hakko Kirin Co., Ltd. | Dérivé du pentadiènamide |
| WO2012072512A1 (en) * | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists |
| JP2014514286A (ja) * | 2011-03-25 | 2014-06-19 | アッヴィ・インコーポレイテッド | Ｔｒｐｖ１拮抗薬 |
| JP2014510768A (ja) * | 2011-04-11 | 2014-05-01 | グラクソ グループ リミテッド | Ｔｒｐｖ１アンタゴニストとしてのｎ−シクロブチルイミダゾピリジンメチルアミン |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
Non-Patent Citations (1)
| Title |
|---|
| ERIC A VOIGHT ET AL.: ""Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature"", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 20, no. 9, JPN6025052564, 30 June 2010 (2010-06-30), pages 1107 - 1122, ISSN: 0005760283 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL307189A (en) | 2023-11-01 |
| AU2022244467A1 (en) | 2023-10-12 |
| EP4313951A1 (en) | 2024-02-07 |
| AR125196A1 (es) | 2023-06-21 |
| PY2221203A (es) | 2022-11-24 |
| UY39681A (es) | 2022-10-31 |
| US12435040B2 (en) | 2025-10-07 |
| MX2023011377A (es) | 2023-10-06 |
| US11845730B2 (en) | 2023-12-19 |
| WO2022201097A1 (en) | 2022-09-29 |
| CN117062804A (zh) | 2023-11-14 |
| BR112023019496A2 (pt) | 2023-12-05 |
| US20220324811A1 (en) | 2022-10-13 |
| US20240308965A1 (en) | 2024-09-19 |
| TW202304864A (zh) | 2023-02-01 |
| CA3214066A1 (en) | 2022-09-29 |
| KR20230162660A (ko) | 2023-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4025574B1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| US12246008B2 (en) | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | |
| US10550102B2 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| CN109153636B (zh) | 作为双重lsd1/hdac抑制剂的环丙基-酰胺化合物 | |
| US12435040B2 (en) | 1,3-substituted cyclobutyl derivatives and uses thereof | |
| EP3164396B1 (en) | Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | |
| US9765067B2 (en) | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | |
| EP4253373A1 (en) | Heteroaryl carboxamide compound | |
| JP2023513373A (ja) | Ｐ２ｘ３修飾薬 | |
| WO2024259171A2 (en) | Keap1 inhibitors and uses thereof | |
| AU2020394597B2 (en) | 1,2,4-oxadiazole derivatives as liver X receptor agonists | |
| JP2018537488A (ja) | インダン誘導体、ならびに可溶性グアニル酸シクラーゼ活性化剤としてのその使用 | |
| CA3211505A1 (en) | Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof | |
| BR122025005591B1 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3- substituída, combinação farmacêutica, e kit | |
| BR122025005591A2 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit | |
| BR112023019496B1 (pt) | Derivados de ciclobutila 1,3-substituída, e composição farmacêutica | |
| EA050893B1 (ru) | Производные 1,3-замещенного циклобутила и способы их применения | |
| RU2823231C1 (ru) | Соединение-антагонист PD-L1 | |
| TW202604533A (zh) | ｐ５３突變體穩定劑及其用途 | |
| HK1263406A1 (en) | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250321 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250321 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251204 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251223 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260319 |